Biodesix Statistics
Total Valuation
Biodesix has a market cap or net worth of $235.93 million. The enterprise value is $283.93 million.
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biodesix has 10.11 million shares outstanding. The number of shares has increased by 14.97% in one year.
| Current Share Class | 10.11M |
| Shares Outstanding | 10.11M |
| Shares Change (YoY) | +14.97% |
| Shares Change (QoQ) | +19.73% |
| Owned by Insiders (%) | 42.18% |
| Owned by Institutions (%) | 28.19% |
| Float | 4.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.46 |
| Forward PS | 2.04 |
| PB Ratio | 25.83 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.82, with a Debt / Equity ratio of 8.06.
| Current Ratio | 2.82 |
| Quick Ratio | 2.42 |
| Debt / Equity | 8.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.16 |
Financial Efficiency
Return on equity (ROE) is -316.53% and return on invested capital (ROIC) is -20.06%.
| Return on Equity (ROE) | -316.53% |
| Return on Assets (ROA) | -17.48% |
| Return on Invested Capital (ROIC) | -20.06% |
| Return on Capital Employed (ROCE) | -31.57% |
| Weighted Average Cost of Capital (WACC) | 7.77% |
| Revenue Per Employee | $287,713 |
| Profits Per Employee | -$95,680 |
| Employee Count | 334 |
| Asset Turnover | 1.06 |
| Inventory Turnover | 13.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +332.38% in the last 52 weeks. The beta is 0.59, so Biodesix's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | +332.38% |
| 50-Day Moving Average | 14.68 |
| 200-Day Moving Average | 11.08 |
| Relative Strength Index (RSI) | 80.19 |
| Average Volume (20 Days) | 76,968 |
Short Selling Information
The latest short interest is 104,666, so 1.04% of the outstanding shares have been sold short.
| Short Interest | 104,666 |
| Short Previous Month | 106,463 |
| Short % of Shares Out | 1.04% |
| Short % of Float | 2.34% |
| Short Ratio (days to cover) | 1.36 |
Income Statement
In the last 12 months, Biodesix had revenue of $96.10 million and -$31.96 million in losses. Loss per share was -$3.93.
| Revenue | 96.10M |
| Gross Profit | 78.48M |
| Operating Income | -25.30M |
| Pretax Income | -31.96M |
| Net Income | -31.96M |
| EBITDA | -19.67M |
| EBIT | -25.30M |
| Loss Per Share | -$3.93 |
Full Income StatementBalance Sheet
The company has $25.57 million in cash and $73.57 million in debt, giving a net cash position of -$48.00 million or -$4.75 per share.
| Cash & Cash Equivalents | 25.57M |
| Total Debt | 73.57M |
| Net Cash | -48.00M |
| Net Cash Per Share | -$4.75 |
| Equity (Book Value) | 9.13M |
| Book Value Per Share | 0.90 |
| Working Capital | 26.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$24.84 million and capital expenditures -$266,000, giving a free cash flow of -$25.10 million.
| Operating Cash Flow | -24.84M |
| Capital Expenditures | -266,000 |
| Depreciation & Amortization | 5.63M |
| Net Borrowing | 9.98M |
| Free Cash Flow | -25.10M |
| FCF Per Share | -$2.48 |
Full Cash Flow StatementMargins
Gross margin is 81.66%, with operating and profit margins of -26.33% and -33.26%.
| Gross Margin | 81.66% |
| Operating Margin | -26.33% |
| Pretax Margin | -33.26% |
| Profit Margin | -33.26% |
| EBITDA Margin | -20.47% |
| EBIT Margin | -26.33% |
| FCF Margin | n/a |
Dividends & Yields
Biodesix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.97% |
| Shareholder Yield | -14.97% |
| Earnings Yield | -13.54% |
| FCF Yield | -10.64% |
Analyst Forecast
The average price target for Biodesix is $30.83, which is 32.09% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.83 |
| Price Target Difference | 32.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 20.70% |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on September 15, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Biodesix has an Altman Z-Score of -6.51 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.51 |
| Piotroski F-Score | 4 |